Riskpilot← Back to searchSign inGet full accessNitrograf Bioanalys Aktiebolag
ABActiveOrg 5565209995Engineering activities and related technical consultancy · NACE 7112Est. 19950 employees
Revenue 2025
SEK 0
EBITDA margin
—
-15% vs 2024
Equity ratio
5.0%
Financial strength
Net profit 2025
SEK -6K
-153% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -15K | -15% |
| Net profit | SEK -6K | -153% |
| Total assets | SEK 2,2M | +2% |
| Equity | SEK 113K | -5% |
| Employees | 0 | — |
Legal name
Nitrograf Bioanalys Aktiebolag
Org number
5565209995
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
18 juli 1995
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva kunskapsförmedling och teknikutveckling företrädesvis inom kraftverksindustrin och de medicinska och hemtekniska områdena, handel och utveckling av patenträttigheter, handel med värdepapper och fast egendom ävensom idka därmed förenlig verksamhet.
Address
Email
veronica.agrenius@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −14 | −9 | −13 | −13 | −15 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −14 | −9 | −13 | −13 | −15 |
| Net financials | 161 | 23 | 6 | 24 | 10 |
| Profit before tax | −175 | 14 | −7 | 11 | −6 |
| Tax | −0 | — | — | — | — |
| Net profit | −175 | 14 | −7 | 11 | −6 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 129 | 2 201 | 2 207 | 2 205 | 2 249 |
| Equity | 101 | 115 | 108 | 119 | 113 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 2 027 | 2 086 | 2 099 | 2 086 | 2 136 |
| Total debt | 2 027 | 2 086 | 2 099 | 2 086 | 2 136 |
EBITDA margin
-1534700.0%
This company
15.8%
Market median
-9713391% vs market
20212025
Equity ratio
5.0%
This company
38.2%
Market median
-87% vs market
20212025
Return on equity
-5.0%
This company
18.4%
Market median
-127% vs market
20212025
Net profit margin
-568700.0%
This company
8.1%
Market median
-7021088% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
18.85×
This company
0.62×
Market median
-2940% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nitrograf Bioanalys Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Erik Agrenius Gustafsson | Deputy Board Member | 0 companies |
| Olga Veronica Agrenius | Board of Directors | 0 companies |